A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus

NCT06202079 ↗

Phase 2 Completed 179 enrolled Gan and Lee Pharmaceuticals, USA

RandomizedParallel-groupOpen-labelTreatment

Summary

This study compares the efficacy, safety, and tolerability of once-weekly GZR4 Injection versus once-daily insulin degludec in patients with type 2 diabetes mellitus in inadquete control on oral antidiabetic drug (OAD) therapy or OAD Therapy in combination with basal insulin.

Timeline

Start: 2023-08-11
Primary completion: 2024-07-13
Completion: 2024-08-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GZR4	Unknown	—	Subcutaneous
Comparator	insulin degludec	Protein / enzyme biologic	—	Subcutaneous

A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus

Summary

Timeline

Drugs

Indications